Islet-cell metabolism during insulin release. Effects of glucose, citrate, octanoate, tolbutamide, glucagon and theophylline.
1. Concentrations of glucose 6-phosphate and 6-phosphogluconate were studied in islets of Langerhans isolated from rat pancreas and incubated in the presence of various agents that induce insulin release. 2. In response to rising concentrations of extracellular glucose (2-10mm) there is a linear increase in the intracellular concentration of glucose 6-phosphate, though this is not the case for 6-phosphogluconate, the intracellular concentration of which only increases when the external glucose concentration exceeds 5mm. 3. Tolbutamide, octanoate and citrate, all of which promote insulin secretion from isolated islets, increase the intracellular concentrations of glucose 6-phosphate and 6-phosphogluconate. The results obtained in the presence of octanoate and citrate are compatible with an inhibitory effect of citrate on islet-cell phosphofructokinase. 4. Theophylline and glucagon when incubated with islets in vitro promote insulin release and cause a rise in 6-phosphogluconate concentration and not in that of glucose 6-phosphate. 5. It is suggested that the further metabolism of glucose 6-phosphate through a pathway other than glycolysis is essential for insulin release. One such pathway involves its oxidation to 6-phosphogluconate, which seems to be a necessary accompaniment of insulin secretion due to glucose. The possibility that agents other than glucose promote insulin release by enhancing the oxidation of glucose 6-phosphate through this pathway is discussed.
D000818:Animals; D002210:Caprylates / Q000494:pharmacology; D002951:Citrates / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology; D005942:Gluconates / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology; D006019:Glycolysis; D006600:Hexosephosphates / Q000378:metabolism*; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000032:analysis / Q000378:metabolism*; D010084:Oxidation-Reduction; D010732:Phosphofructokinase-1 / Q000037:antagonists & inhibitors; D051381:Rats; D012636:Secretory Rate / Q000187:drug effects; D013806:Theophylline / Q000494:pharmacology; D014044:Tolbutamide / Q000494:pharmacology
D002210:Caprylates; D002951:Citrates; D005942:Gluconates; D006600:Hexosephosphates; D007328:Insulin; D005934:Glucagon; D014044:Tolbutamide; D013806:Theophylline; D010732:Phosphofructokinase-1; D005947:Glucose